Oakwood Investors I

Portfolio Companies

United Therapeutics Corporation (NasdaqNM: UTHR) develops pharmaceuticals to treat vascular disease, including pulmonary hypertension and peripheral vascular disease, as well as selected other chronic conditions.

Carbon Medical Technologies, Inc. was founded to develop, manufacture and market innovative, curative therapies, primarily for the treatment of urinary incontinence. In October 1999, Carbon Medical Technologies received approval from the FDA to sell Durasphere, an injectible bulking agent for the treatment of stress urinary incontinence.

EndiCOR Medical, Inc. (acquired by ev3, Inc.) is a leading company in the development of next-generation interventional devices specifically designed to treat cardiovascular disease. EndiCOR's principal product is the X-SIZER® Catheter System, an easy-to-use, low cost, fully disposable device that combines vacuum with a spinning helix cutter located within the tip of a catheter. The X-SIZER® is designed to easily remove blockages, such as blood clots and soft tissue obstructions, from blood vessels to restore flow.    

LipoScience, Inc. is a diagnostic testing and information processing company that is pioneering new medical applications of nuclear magnetic resonance (NMR) spectroscopy which will enable physicians to diagnose coronary heart disease (CHD) risk more accurately, and determine on an individual basis the most cost-effective therapeutic strategy for risk reduction.

Medical Device Alliance, Inc. (acquired by ArthroCare Corporation) manufactures and markets devices for body fat removal through liposuction. MDA's LySonix 2000 Ultrasonic System causes less trauma to patient tissue, less blood loss, reduced damage to adjacent nerves and cells, less post-operative bruising and swelling, shorter recovery period and the ability to remove more fat per procedure through the use of ultrasound.

Nobex Corporation is a development stage drug delivery company specializing in proprietary polymer-based systems for the delivery and stabilization of protein and peptide drugs. The most advanced products in development are an oral insulin for treating Type II diabetes; oral APAZA™ for treating inflammatory bowel disease; and an oral calcitonin for treating osteoporosis.

Novocell, Inc. is involved in the research and development of minimally invasive, encapsulated cellular transplants for the treatment of diabetes. Novocell's technology is designed to improve the regulation of blood glucose while significantly decreasing or eliminating the need for insulin injections, hence delaying or preventing the medical complications often accompanying the disease.

Stereotaxis, Inc. (NasdaqNM: STXS) is a development stage medical device company engaged in the field of image guided interventional surgery. Stereotaxis' Magnetic Surgery System (MSS) is composed of a surgical work station which utilizes super-conducting magnets and digital computer imaging to guide disposable instruments, including magnetic tipped catheters, endoscopes and other medical instruments, to remote areas of a patient's brain or vascular system.